Hemp 15 mg & 50 mg Capsule Absorption

Gaia Herbs Inc.30 enrolled

Overview

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

This study is designed to determine the time to maximum plasma concentration of CBD and CBD-A after an oral dose of standardized full spectrum hemp extract over a 4-hour timeline. This study is designed to include two arms. Each arm will be delivered a different concentration of standardized full spectrum hemp extract, either 15 mg or 50 mg. Throughout the course of the study all participants will be asked to provide four (4) plasma samples, 10 randomly selected participants will be asked to provide five (5) plasma samples. Samples will then be evaluated using a validated LC-MS/MS method to develop a blood concentration time curve in order to determine time to reach maximum blood concentration. This trial is double-blinded with two arms enrolling only healthy individuals. The participants randomized for a fifth blood draw will be randomly selected from these two arms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Absorption; Chemicals

Interventions

15 mg/g Full Spectrum Hemp ExtractDIETARY_SUPPLEMENT

HPMC capsules containing full spectrum standardized hemp extract in liquid form.

50 mg/g Full Spectrum Hemp ExtractDIETARY_SUPPLEMENT

HPMC capsules containing full spectrum standardized hemp extract in liquid form.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Ages 18 - 65. 4. In good general health as evidenced by medical history as indicated by oral confirmation of study participant. 5. Ability and willingness to suspend the use of any other herbal dietary supplements for 48 hours prior the first clinical visit associated with this study. 6. Ability and willingness to abstain from alcohol use for 12 hours prior to the first clinical visit. 7. Cannabis and CBD naïve for 60 days or more prior to enrolling in the study. 8. Ability and willingness to abstain from food for 6 hours prior to the first clinical visit. Exclusion Criteria: 1. Current use of regular medication for a chronic condition. 2. Current pregnancy or lactation. 3. Plans to become pregnant during the intended duration of the study. 4. Known allergic reactions to hemp flower. 5. Known severe food allergies.

Locations (1)

Appalachian College of Pharmacy

Oakwood, Virginia, United States

Outcomes

Primary Outcomes

Time to maximum plasma concentration

To determine the time to maximum plasma concentration of cannabidiol (CBD) and cannabidiol acid (CBD-A) from an oral delivery of a single dose of standardized 15 mg or 50 mg full spectrum hemp extract

Time frame: Over 4 hours

Secondary Outcomes

Detectable THC

To determine if the oral delivery of a full spectrum hemp extract standardized to less than 0.3% ∆\^9- tetrahydrocannabinol (THC) results in detectable amounts of THC in plasma.

Time frame: Over 4 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.